Trial Profile
To Evaluate Long-Term Efficacy, Safety and Tolerability Data in a Real Life Setting of (Delta-9-tetrahydrocannabinol) THC/cannabidiol (CBD) Oromucosal Spray in Patients With Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Dec 2015
Price :
$35
*
At a glance
- Drugs Nabiximols (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 07 Dec 2015 New trial record
- 26 Nov 2015 Results published in the Journal of Clinical Pharmacology